InvestWiser

Fluoguide AS

FLUONasdaq StockholmHealthcareMarket value 517 m SEK
31.60SEK +12.5%
last day · Price as of 18 November 2026

The answer first

Does Fluoguide beat the market?

No, Fluoguide has not beaten the market over the last year.

Fluoguide−19.4%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 7% of Nordic stocks

    • Quality45
    • Value2
    • Trend26

    No. 170 of 195 in healthcare

Max for seven days

Follow Fluoguide with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Fluoguide

From today, at a price of 31.60 SEK. Write why you follow Fluoguide, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Fluoguide

Your first answer is free, no account needed.

Do you own Fluoguide, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Fluoguide and a few more. Free, no card.

Past year against the exchange and Super Stock
Fluoguide−19.4%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Fluoguide has fallen 19.4% over the past year, including dividends.
  • Overall, Fluoguide ranks better than 7% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 73.6%. The price is 82.2% below its peak now.

What do analysts think of Fluoguide?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

7

Quality, value and trend together. Better than 7% of Nordic stocks.

No. 170 of 195 in healthcare

Quality45
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 139 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.90
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−150.4%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 187 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity10.8
  • P/SPrice divided by salesnegative earnings
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend26
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 109 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−0.3%
  • 6 months−26.3%
  • 9 months−12.0%
  • 12 months−19.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+5.0%
3 years, per year
−28.1%
5 years, per year
−18.6%
Year to date
−7.9%
Largest fall, 3 years
−73.6%
From a peak to the bottom
From the peak now
−82.2%
How far the price is from the peak
Volatility, 1 year
57.0%
How much the price swings over a year
Beta, 1 year
−0.12
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Fluoguide

One fund we follow owns Fluoguide. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Fluoguide

Fluoguide AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.

See the full analysis of Fluoguide.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market